ID: MRFR/Pharma/2779-HCR | 78 Pages | Author: Kinjoll Dey | June 2023
Seasonal Affective Disorder Market Size was valued at USD 0.85 billion in 2022 and is projected to grow from USD 0.88 Billion in 2023 to USD 1.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.5% during the forecast period (2023 - 2030). The rise in the senior population and growing information about seasonal affective Disorder are projected to be the market drivers for the growth of the seasonal affective disorder market during the forecast period. Furthermore, the shift in lifestyle is expected to move the seasonal affective disorder market forward.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Seasonal Affective Disorder Market Trends
The rising prevalence of seasonal affective Disorder and depression, as well as increased R&D activities, are driving market expansion. For example, according to American Psychiatric Association data updated in October 2020, seasonal affective Disorder (SAD), a kind of depression that peaks in the winter, affects 5% of adults in the United States.
Furthermore, according to the National Health Service, United Kingdom update in September 2021, more than a third of 16-year-olds have SAD, suspect they have SAD or feel poor moods in the fall and winter. Seasonal Affective Disorder affects one out of every twenty people in the UK. According to the research, women are more likely than males to report experiencing a bad mood in the autumn and winter (18.28 percent vs. 12.87 percent). Such factors have enhanced the Seasonal Affective Disorder market CAGR across the globe in recent years.
Furthermore, the Anxiety and Depression Foundation facts and data updated in June 2022 show that generalized anxiety disorder affects 6.8 million adults, or 3.1% of the US population, each year. As a result, increased incidences of depression and SADs around the world are likely to boost overall Seasonal Affective Disorder market revenue over the forecast period.
Seasonal Affective Disorder Market Segment Insights
Seasonal Affective Disorder Type Insights
The global Seasonal Affective Disorder market segmentation, based on type, includes Fall and Winter Sad, and Others. The fall and winter SAD segments continue to dominate the global Seasonal Affective Disorder market revenue and will do so throughout the projection period. Oversleeping, excessive weight gain, fatigue or poor energy levels, lack of physical activity, overeating, and lack of exposure to sunlight in winter are all factors that contribute to this. Low exposure to sunshine, for the record, lowers serotonin and melatonin levels, causing unhappiness, mood swings, and disrupting sleep patterns. The variables described above are anticipated to raise demand for novel therapeutic options such as enhanced phytotherapy and psychotherapy, among others.
Seasonal Affective Disorder Diagnosis Insights
The global Seasonal Affective Disorder market data has been bifurcated by diagnosis into Physical Exam, Laboratory Tests, Psychological Evaluation, and Others. Over the projection period, the psychological evaluation segment is expected to increase at a high rate in global Seasonal Affective Disorder industry. Personality tests, vocational tests, neuropsychological tests, aptitude tests, and direct observation assessments are all part of the section. The growing number of organisations and service providers offering psychological evaluation, as well as the existence of a large number of qualified clinical psychologists, organisational behaviourists, neuropsychiatrists, and statisticians, are driving this trend. PSYCHOMATRIX, for example, is a leading organisation involved in the distribution, publication, training, and selling of psychological examinations. Psychiatrists' hospitals, school psychologists, psychologists' educational institutes, clinical psychologists, neuropsychologists, health psychologists, and forensic psychologists, among others, employ the aforementioned tests widely.
Seasonal Affective Disorder Treatment Insights
Based on treatment, the global Seasonal Affective Disorder market segmentation includes Light Therapy, Medications, And Others. Light therapy is gaining market share in the SAD industry due to the increasing prevalence of SAD and the introduction of innovative therapies. When used with antidepressants, light therapy has fewer negative effects and is both safe and effective. Additional factors boosting the category include the simple accessibility of products through online platforms and increased awareness among end-users regarding the usage of light therapy products. Similarly, is fueling market expansion. Hence, rising healthcare expenditure in emerging markets such as China and India positively impacting the market growth.
FIGURE 1: GLOBAL SEASONAL AFFECTIVE DISORDER MARKET, BY TREATMENT, 2022 & 2030 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Seasonal Affective Disorder End User Insights
Based on End Users, the global Seasonal Affective Disorder industry has been segmented into Hospitals, Clinics, households, Medical Research Centers, and Others.
Multispecialty hospitals held the largest segment share in 2022, owing to the rapid adoption of advanced Seasonal Affective Disorder surgery products and the availability of skilled medical staff. Moreover, increasing government initiatives to improve the healthcare infrastructure, and the growing number. Seasonal Affective Disorder surgeries such as minimally invasive spine surgery and others are expected to bolster at a CAGR of 3.17% during the assessed timeline.
The fastest growing and dominating segment in the Seasonal Affective Disorder industry is household. The household segment is being pushed primarily by increasing public awareness of self-care, the availability of online training sessions for enhancing mental health, the increasing use of smartphones and internet usage, and the rising use of mental health applications. Online classes and mental treatment sessions are already gaining popularity among the general public since they provide a plethora of services at very inexpensive pricing. In accordance with this, a number of significant firms are heavily investing in the development of effective digital health apps at competitive rates.
Seasonal Affective Disorder Regional Insights
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World.
North America is estimated to hold a considerable proportion of the seasonal affective disorder pharmaceuticals market and is predicted to show a similar pattern without notable volatility over the forecast period. Seasonal affective Disorder (SAD) is a major depressive disease with a seasonal pattern that has been identified and classified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnostic categorization system, which was published in March 2022. Furthermore, the increased prevalence of seasonal affective Disorder is expected to fuel regional market expansion. According to a National Center for Biotechnology Information (NCBI) study published in October 2020, roughly 14% of the adult population in the United States suffers from the winter blues, a milder type of seasonal mood fluctuation.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Seasonal Affective Disorder market accounts for the second-largest market share due to an increase in the number of people suffering from seasonal depression. Furthermore, the changing lifestyle and increased knowledge about various mental disorders will drive the growth of the seasonal affective disorder market in the area throughout the forecast period. Further, the Germany Seasonal Affective Disorder market held the largest market share, and the UK Seasonal Affective Disorder market was the fastest growing market in the European region.
The Asia-Pacific Seasonal Affective Disorder Market is expected to grow at the fastest CAGR from 2022 to 2030. Because of advancements in health care, Asia-Pacific is expected to see considerable growth in the seasonal affective disorder market. Furthermore, the simple availability of therapies and goods is expected to drive the expansion of the seasonal affective disorder market in the region in the coming years. Moreover, China Seasonal Affective Disorder market held the largest market share, and the India Seasonal Affective Disorder market was the fastest growing market in the Asia-Pacific region.
Seasonal Affective Disorder Key Market Players & Competitive Insights
Major market players are investing heavily in R&D in order to expand their product lines, which will help the Seasonal Affective Disorder market grow even more. Market participants are also pursuing a variety of strategic activities to expand their global footprint, including market developments such as new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other companies. Competitors in Seasonal Affective Disorder industry must supply cost-effective merchandise in order to expand and thrive in an increasingly competitive and rising market environment.
Manufacturing locally to lower operating costs is one of the key business tactics used by manufacturers in the worldwide Seasonal Affective Disorder industry to benefit customers and increase the market sector. In recent years, the Seasonal Affective Disorder industry has supplied medicine with some of the most significant benefits. The Seasonal Affective Disorder market major player such as AbbVie, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Henry Schein, Circadian Optics, and Others.
Bayer is a multinational corporation with primary capabilities in the life sciences of healthcare and nutrition. The company's goods and services are designed to help people and the world thrive by assisting efforts to solve the tremendous global problems posed by a growing and ageing global population. Bayer is a multinational corporation with operations in 83 countries.
Henry Schein, Inc. is a health care solutions firm powered by a network of people and technology. The Company's network of trusted advisers, which includes more than 22,000 Team Schein Members worldwide, provides more than 1 million customers with more than 300 valuable solutions that assist improve operational success and clinical outcomes. Its Business, Clinical, Technology, and Supply Chain solutions make it easier for office-based dentistry and medical practitioners to provide great service. These solutions also benefit dentistry laboratories, government and institutional health care clinics, and other alternative care locations.
Key Companies in the Seasonal Affective Disorder market includes
Seasonal Affective Disorder Industry Developments
February 2022: Granules, the United States Food and Drug Administration has granted India permission to market Bupropion Hydrochloride extended-release tablets in the United States to treat major depressive Disorder and seasonal affective Disorder.
June 2021: Alkermes plc received approval from the US Food and Drug Administration for a novel medicine for schizophrenia and bipolar Disorder. Lybalvi is a medicine that combines the active ingredient of Eli Lilly's Zyprexa with a newer chemical compound called samidorphan.
Seasonal Affective Disorder Market Segmentation
Seasonal Affective Disorder Type Outlook
Seasonal Affective Disorder Diagnosis Outlook
Seasonal Affective Disorder Treatment Outlook
Seasonal Affective Disorder End User Outlook
Seasonal Affective Disorder Regional Outlook
Rest of the World
|Market Size 2022||USD 0.85 billion|
|Market Size 2023||USD 0.88 billion|
|Market Size 2030||USD 1.15 billion|
|Compound Annual Growth Rate (CAGR)||4.5% (2023-2030)|
|Market Forecast Period||2023-2030|
|Historical Data||2018 - 2021|
|Market Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product Type, Operating Platforms, and Region|
|Geographies Covered||North America, Europe, Asia Pacific, and Rest of the World|
|Countries Covered||The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil|
|Key Companies Profiled||AbbVie, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Henry Schein, Circadian Optics, and Others.|
|Key Market Opportunities||Creating Awareness Across Regions|
|Key Market Dynamics||Increasing Prevalence of Seasonal Affective Disorder and Depression Growing R&D Activities and Rising Number of Treatment Options|
The global Seasonal Affective Disorder market size was valued at USD 0.85 Billion in 2022.
The global market is projected to grow at a CAGR of 4.7% during the forecast period, 2022-2030.
North America had the largest share in the global market
The key players in the market are AbbVie, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Henry Schein, and Circadian Optics.
The Fall and Winter SAD category dominated the market in 2022.
The psychological evaluation had the largest share in the global market.
Key Questions Answered
Why Choose Market Research Future?